168 related articles for article (PubMed ID: 38642459)
1. Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.
Crawford DE; Albala D; Garnick MB; Hahn AW; Maroni P; McKay RR; Miner M; Orio Ⅲ P; Pandit K; Sellinger S; Yu EY; Eckel RH
Can J Urol; 2024 Apr; 31(2):11820-11825. PubMed ID: 38642459
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
3. A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.
Crawford ED; Garnick MB; Eckel RH; Miner MM; Freedland SJ; Pachynski RK; Wassersug RJ; Rosenberg MT; Walker LM; Fairman C; Curley T; Crosby M; Lin PH; Hafron JM
Urol Pract; 2024 Jan; 11(1):18-29. PubMed ID: 37917591
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
6. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
7. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
Butler SS; Mahal BA; Moslehi JJ; Nohria A; Dee EC; Makkar R; Whitbeck A; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2021 Jul; 127(13):2213-2221. PubMed ID: 33905530
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
[TBL] [Abstract][Full Text] [Related]
11. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
[TBL] [Abstract][Full Text] [Related]
12. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
15. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
Klemm J; von Deimling M; Fisch M; Kramer G; Tilki D; Steuber T; von Amsberg G; Hengstenberg C; Shariat SF
Urologie; 2024 Mar; 63(3):262-268. PubMed ID: 37874334
[TBL] [Abstract][Full Text] [Related]
16. Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer.
Gilbert SE; Tew GA; Bourke L; Winter EM; Rosario DJ
Exp Physiol; 2013 Sep; 98(9):1401-10. PubMed ID: 23666791
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
20. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.
Newton RU; Taaffe DR; Spry N; Gardiner RA; Levin G; Wall B; Joseph D; Chambers SK; Galvão DA
BMC Cancer; 2009 Jun; 9():210. PubMed ID: 19563641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
